5 stories mentioning THCUpdated 17d ago
Every FINWIRES story that references THC, newest first.
J Robert Kerrey, Director, on May 28, 2026, sold 5,638 shares in Tenet Healthcare (THC) for $983,920. Following the Form 4 filing with the SEC, Kerrey has control over a total of 16,804 common shares of the company, with 16,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/70318/000119312526249167/xslF345X05/ownership.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $200 from $260, 11.4x our 2026 EPS estimate (up to $17.56 from $17.33; 2027 estimate up to $18.00 from $17.85), a discount to the company's three-year historical forward average of 12.9x. We think THC's valuation balances recent deleveraging efforts and a stronger margin profile than in previous years against policy headwinds, including cuts to Medicaid coverage under the OBBBA legislation and the recent expiration of ACA enhanced premium tax credits, which increases risk of higher uncompensated care. Same-facility ACA exchange admissions fell 10% Y/Y in Q1, and THC guides for a 20% reduction in ACA exchange patient volumes for 2026 and anticipates a negative $250 million impact on adjusted EBITDA. While we expect THC to revisit annual guidance in Q2 earnings, at which point a clearer picture of the insurance coverage landscape is likely, we look favorably on the company maintaining its annual inpatient/outpatient volume guidance for now.
Tenet Healthcare (THC) has an average rating of buy and mean price target of $254.05 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $184.94, Change: $+7.91, Percent Change: +4.47%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Tenet Healthcare delivered Q1 adjusted EPS of $4.82 (+10.6% Y/Y), beating consensus by $0.65, while net operating revenues of $5.368B (+2.8% Y/Y) missed consensus by 0.5%. Consolidated adjusted EBITDA of $1.162B remained flat at 21.6% margins vs. the prior-year quarter. The Ambulatory Care segment supported the performance with revenues up 10.6% to $1.320B and adjusted EBITDA growing 6.1% to $484M, though margins compressed 150bps to 36.7%. The Hospital segment faced headwinds from ACA enhanced premium tax credit expiration, with revenues up only 0.5% to $4.048B and adjusted EBITDA declining 4.1% to $678M as margins compressed 80bps to 16.7%. The strong EPS beat and maintained margin guidance suggest confidence in underlying operational trends despite volume headwinds, in our view. THC maintained its FY 2026 adjusted EBITDA guidance of $4.485B-$4.785B while raising the adjusted EPS midpoint 1.2% to $17.53, supported by share repurchases.
Tenet Healthcare (THC) shares were trading slightly higher Thursday as the company reported higher Q1 adjusted earnings and revenue.The company reported Q1 adjusted EPS of $4.82, up from $4.36 a year earlier. Analysts polled by FactSet expected $4.17.Net operating revenue for the quarter ended March 31 was $5.37 billion, up from $5.22 billion a year earlier.Analysts surveyed by FactSet expected $5.39 billion.For 2026, the company expects adjusted diluted earnings per share between $16.38 to $18.68, compared with $16.19 to $18.47 previously. Analysts expect $17.22.Full year revenue guidance was maintained at $21.50 billion to $22.30 billion. Analysts expect $22.01 billion.Price: $180.51, Change: $+0.31, Percent Change: +0.17%
